Q2 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

Zymeworks Inc. (NYSE:ZYME - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Zymeworks in a note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.56) for the quarter, up from their prior estimate of ($0.59). The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks' Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.38) EPS.

ZYME has been the topic of several other reports. Citigroup increased their price objective on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. HC Wainwright lifted their price target on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Finally, Lifesci Capital started coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Zymeworks Stock Performance

Zymeworks stock traded down $0.93 during mid-day trading on Thursday, hitting $11.92. 232,520 shares of the company traded hands, compared to its average volume of 589,307. The stock has a market cap of $829.36 million, a price-to-earnings ratio of -7.95 and a beta of 1.24. Zymeworks has a one year low of $8.21 and a one year high of $17.70. The stock has a fifty day moving average price of $11.99 and a 200-day moving average price of $13.50.

Insider Transactions at Zymeworks

In other news, Director Ecor1 Capital, Llc acquired 73,953 shares of the firm's stock in a transaction on Wednesday, April 16th. The stock was acquired at an average price of $11.16 per share, with a total value of $825,315.48. Following the completion of the purchase, the director now directly owns 17,773,727 shares in the company, valued at approximately $198,354,793.32. This trade represents a 0.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought a total of 1,350,347 shares of company stock worth $16,137,499 in the last ninety days. Insiders own 1.92% of the company's stock.

Hedge Funds Weigh In On Zymeworks

Institutional investors have recently modified their holdings of the stock. Blackstone Inc. raised its holdings in shares of Zymeworks by 2,171.4% in the fourth quarter. Blackstone Inc. now owns 569,715 shares of the company's stock valued at $8,341,000 after acquiring an additional 544,633 shares in the last quarter. Walleye Capital LLC purchased a new position in Zymeworks during the 4th quarter worth $6,629,000. Schroder Investment Management Group acquired a new position in Zymeworks during the 4th quarter valued at about $4,892,000. Assenagon Asset Management S.A. boosted its holdings in Zymeworks by 93.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after acquiring an additional 311,107 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Zymeworks by 565.8% during the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company's stock valued at $4,833,000 after acquiring an additional 280,544 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.